Clinical Trial Update: Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa [Phase 2]

View source ↗

Summary

Open-label extension study assessing safety of SD-101 cream in Epidermolysis Bullosa; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• SD-101 cream (null)

Snippet

Sponsor: Scioderm, Inc. | Conditions: Epidermolysis Bullosa | Phase 2 | Status: TERMINATED | Results posted: 2019-11-04